- The disease
- Bladder cancer is among the more common cancers in developed countries, and a significant proportion of cases first present as hematuria (blood in the urine). Hematuria is investigated primarily through cystoscopy, a procedure in which a camera is inserted into the bladder to look for tumours. Many patients referred for cystoscopy do not have bladder cancer, meaning a large share of procedures return normal findings. Identifying which patients are at lower risk before cystoscopy could reduce the number of unnecessary invasive procedures.
- What the asset is trying to do
- Cxbladder Triage is a urine-based gene expression biomarker panel. It measures the levels of messenger RNA from a set of genes associated with bladder cancer in a urine sample, producing a result that indicates the likelihood of bladder cancer being present. This differs from cystoscopy, which is a direct visual examination, and from urine cytology, which looks for cancer cells under a microscope. By providing a molecular risk signal from a non-invasive sample, it is intended to help clinicians decide whether to proceed immediately to cystoscopy.
- What the trial is measuring, and why it matters
- The registered trial (NCT06394869) is studying whether use of Cxbladder Triage Plus changes the number of cystoscopies performed in patients presenting with hematuria of unknown cause (per ClinicalTrials.gov NCT06394869). The key question is whether a negative or low-risk test result leads clinicians to safely defer cystoscopy in some patients. Reducing unnecessary cystoscopies is clinically meaningful because the procedure carries discomfort and cost, and health systems perform large volumes of it annually.
- Efficacy benchmarks in this setting
- In published guidelines, cystoscopy combined with upper-tract imaging is the standard diagnostic workup for hematuria; urine cytology is also used as an adjunct and has a reported sensitivity for high-grade bladder cancer of approximately 40-60% and specificity above 90% in some studies (per Tan WS et al, BJU International, 2019). Approved molecular urine tests in the US include UroVysion (FISH-based) and BTA stat/BTA TRAK assays, with performance characteristics reported in their respective FDA clearance summaries. Because Cxbladder Triage's trial (NCT06394869) is still recruiting and has not reported primary endpoint data, any interim figures from earlier studies are not statistically comparable to these benchmarks in the context of this prospective impact study.